Selected Grants
Invasive Candidiasis
Clinical TrialPrincipal Investigator · Awarded by Basilea Pharmaceutica · 2024 - 2028Antibacterial Resistance Leadership Group (ARLG)
ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2013 - 2026HR-BV 3
Clinical TrialPrincipal Investigator · Awarded by Biomeme, Inc. · 2023 - 2024CEC Activities for BPR-CS-009 Ceftobiprole medocaril - WO2
Clinical TrialCo Investigator · Awarded by Basilea Pharmaceutica · 2018 - 2022CEC Activities for BPR-CS-009 Ceftobiprole medocaril
Clinical TrialCo Investigator · Awarded by Basilea Pharmaceutica · 2017 - 2022Vaccine Trial_LOI
ResearchCo Investigator · Awarded by Universitair Medisch Centrum Utrecht · 2019 - 2021Bacteremia Modification 14
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2009 - 2017Mod 11 for Option 3 - Staphylococcal Bacteremia Study
Clinical TrialInvestigator · Awarded by National Institutes of Health · 2009 - 2017Modification No 13 Staphylococcal Bacteremia Study
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2009 - 2017ACHN-490-007 Trial
Clinical TrialPrincipal Investigator · Awarded by Achaogen, Inc · 2016 - 2017Modification No. 8 - Staphylococcal Bacteremia Study
Clinical TrialInvestigator · Awarded by National Institutes of Health · 2009 - 2016Modification No. 5 - Staphylococcal Bacteremia Study
Clinical TrialInvestigator · Awarded by National Institutes of Health · 2009 - 2015A Phase III Multi-Center, Randomized, Open-label, Comparative Study to Assess the Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Intravenous Catheter-Associated Bloodstream Infections (BSI) due to Staphylococci
Clinical TrialFellow · Awarded by National Institutes of Health · 2009 - 2012External Relationships
- Advarra
- Aridis Pharmaceuticals
- Basilea Inc.
- Concert Genetics, Inc
- Karius, Inc.
- PSI CRO AG
- Reminger Co LPA
- SPERO Therapeutics
- UpToDate, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.